Press releases
2026
In this Swedish-language interview, Disruptive Pharma and Guard Therapeutics discuss the proposed reverse takeover announced on 10 June 2026, including the background to the transaction and what the planned combination could mean for Disruptive Pharma's continued development. Watch the interview on YouTube: https://www.youtube.com/watch?v=nYjn5G9jffY&t=74s...
10 June, 2026
Guard Therapeutics has entered into a conditional agreement for a reverse takeover with Disruptive Pharma
Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the ”Company”) has today entered into a conditional agreement with shareholders who together hold approximately 91.3 percent of all outstanding shares in Disruptive Pharma Holding AB (publ) (“Disruptive Pharma”) (the “Majority Shareholders”) regarding the acquisition...
At the DDF Summit 2026 in Berlin, Disruptive Pharma presented an award-winning poster on Formulite®, our bioavailability enhancement platform for poorly soluble oral drugs. The poster, which won the 2026 Poster Competition, summarizes technical and clinical validation data, including improved dissolution, higher drug loading, bioavailability...
7 May, 2026
Case study: Fast-track formulation development
During a visit to a potential partner, the
objective was to rapidly assess the feasibility of formulating a
poorly soluble compound using Formulite® — and generate material
for downstream development without entering a lengthy formulation
program. Approach focused, on-site development sprint was conducted over two days,
combining feasibility...
We are pleased to welcome Ellen Brunzell to Disruptive Pharma. Ellen is a licensed pharmacist and recently completed her PhD in pharmaceutical physical chemistry at Uppsala University. Her research has focused on drug substances, formulation-relevant interactions and peptide aggregation, bringing valuable expertise to our work in pharmaceutical...